Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 10 | 2024 | 176 | 1.820 |
Why?
|
| Breast Neoplasms | 13 | 2022 | 1679 | 1.750 |
Why?
|
| Mastectomy, Segmental | 4 | 2022 | 25 | 1.280 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 532 | 1.110 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2024 | 9 | 0.870 |
Why?
|
| Medically Underserved Area | 1 | 2025 | 118 | 0.850 |
Why?
|
| Prediabetic State | 1 | 2025 | 68 | 0.830 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 309 | 0.730 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 74 | 0.710 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 242 | 0.670 |
Why?
|
| Heart Failure | 1 | 2023 | 298 | 0.620 |
Why?
|
| Stroke | 1 | 2023 | 348 | 0.600 |
Why?
|
| Receptor, erbB-2 | 8 | 2020 | 149 | 0.590 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 43 | 0.570 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 729 | 0.510 |
Why?
|
| Aged | 12 | 2025 | 7982 | 0.470 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 979 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 744 | 0.460 |
Why?
|
| Insurance, Health | 2 | 2014 | 143 | 0.430 |
Why?
|
| United States | 8 | 2025 | 5072 | 0.420 |
Why?
|
| Humans | 28 | 2025 | 42163 | 0.410 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2022 | 76 | 0.410 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 502 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 209 | 0.370 |
Why?
|
| Female | 15 | 2025 | 24018 | 0.360 |
Why?
|
| Retrospective Studies | 4 | 2025 | 2485 | 0.350 |
Why?
|
| Models, Economic | 2 | 2024 | 30 | 0.340 |
Why?
|
| Prostatic Neoplasms | 6 | 2015 | 1068 | 0.330 |
Why?
|
| Medicare | 2 | 2022 | 326 | 0.310 |
Why?
|
| Middle Aged | 11 | 2025 | 11819 | 0.250 |
Why?
|
| Florida | 7 | 2015 | 461 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 174 | 0.230 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 233 | 0.220 |
Why?
|
| Health Care Sector | 1 | 2024 | 10 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2023 | 362 | 0.210 |
Why?
|
| Registries | 4 | 2014 | 431 | 0.210 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2803 | 0.210 |
Why?
|
| Liver Transplantation | 1 | 2023 | 37 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2023 | 71 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 1 | 2023 | 56 | 0.200 |
Why?
|
| Myocardial Ischemia | 1 | 2023 | 82 | 0.200 |
Why?
|
| Adult | 10 | 2025 | 13458 | 0.190 |
Why?
|
| Glucosides | 1 | 2022 | 21 | 0.190 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 164 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 49 | 0.180 |
Why?
|
| Logistic Models | 4 | 2023 | 1001 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 188 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 116 | 0.170 |
Why?
|
| Survival Rate | 1 | 2020 | 353 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 117 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 134 | 0.150 |
Why?
|
| Male | 8 | 2025 | 22779 | 0.150 |
Why?
|
| Decision Making | 1 | 2021 | 242 | 0.150 |
Why?
|
| Delayed Diagnosis | 2 | 2014 | 33 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 23 | 0.130 |
Why?
|
| Propensity Score | 1 | 2016 | 58 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 49 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1586 | 0.130 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 428 | 0.120 |
Why?
|
| Risk Factors | 1 | 2023 | 3942 | 0.110 |
Why?
|
| Quality of Life | 1 | 2019 | 599 | 0.110 |
Why?
|
| Thiocarbamates | 1 | 2014 | 5 | 0.110 |
Why?
|
| Androstadienes | 1 | 2014 | 19 | 0.110 |
Why?
|
| Mastectomy | 1 | 2014 | 16 | 0.110 |
Why?
|
| Antineoplastic Protocols | 1 | 2013 | 1 | 0.100 |
Why?
|
| Adolescent | 1 | 2023 | 5950 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 210 | 0.090 |
Why?
|
| Comorbidity | 4 | 2014 | 725 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1221 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 358 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 573 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2015 | 336 | 0.070 |
Why?
|
| Markov Chains | 2 | 2019 | 42 | 0.070 |
Why?
|
| Mass Screening | 2 | 2023 | 531 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 467 | 0.070 |
Why?
|
| Multilevel Analysis | 2 | 2015 | 21 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 959 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 366 | 0.060 |
Why?
|
| Living Donors | 1 | 2023 | 18 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2023 | 39 | 0.050 |
Why?
|
| Graft Survival | 1 | 2023 | 47 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 55 | 0.050 |
Why?
|
| Patient Preference | 1 | 2021 | 55 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2021 | 91 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2023 | 336 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1139 | 0.040 |
Why?
|
| Taiwan | 1 | 2019 | 21 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 53 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 482 | 0.040 |
Why?
|
| Nitriles | 1 | 2019 | 78 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 398 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 139 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 100 | 0.040 |
Why?
|
| Maytansine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Public Health | 1 | 2022 | 405 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 50 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 17 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 663 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 37 | 0.030 |
Why?
|
| Mexico | 1 | 2017 | 286 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 89 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 82 | 0.030 |
Why?
|
| Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
|
| Single Person | 1 | 2013 | 6 | 0.030 |
Why?
|
| Sirolimus | 1 | 2014 | 70 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 90 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2013 | 46 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 64 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 65 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 661 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 177 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 12 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 28 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 115 | 0.020 |
Why?
|
| Life Style | 1 | 2014 | 326 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 249 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 708 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 471 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2014 | 705 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 1019 | 0.020 |
Why?
|